The United States Patent and Trademark Office (USPTO) has published a new patent application, US20260085047A1, filed by Shiratori Pharmaceutical Co., Ltd. The application pertains to a triphenylazole compound, represented by formula (I), and its use as a medicament. Specifically, the invention aims to provide a pharmaceutical composition for the treatment or prevention of synucleinopathy, a class of neurodegenerative diseases.

This publication represents a new patent filing and does not impose immediate regulatory obligations on entities outside of the patent application process itself. Companies involved in pharmaceutical research and development, particularly in the areas of neurology and drug discovery, should note this filing as it pertains to potential future intellectual property and therapeutic advancements in synucleinopathy treatment.